'Wonder drug' a true cancer-buster.Byline: ANI London, Sept 16 (ANI): A promising pill may be able to treat more types of cancer than first thought, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. researchers. The wonder pill can tackle five other forms of the disease - prostate, skin, ovarian, bowel and womb cancer, say scientists. As per lab tests, the drug targets cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer while leaving healthy cells relatively unaffected - meaning fewer side effects Side effects Effects of a proposed project on other parts of the firm. for patients. It belongs to a class called PARP PARP Poly ADP-Ribose Polymerase PARP Planning And Review Process PARP PfP Planning and Review Process (NATO) PARP Pajarito Archaeological Research Project PARP Possible Acknowledgement Returning Period PARP Proxy Attribute Request Protocol inhibitors. The type - olaparib - is already being used to treat some hereditary forms of breast cancer. It was developed by Professor Alan Ashworth and a British team from research charity Breakthrough Breast Cancer Breakthrough Breast Cancer is the United Kingdom's leading breast cancer charity committed to fighting breast cancer through research, campaigning and education. Its essence comes from the thousands of people who are committed to a single vision - , reports The Sun. The team found that the inhibitors killed cancer cells behind 30 per cent of breast cancers - and up to 80 per cent of breast, prostate, melanoma, womb, bowel and ovarian cancers. Ashworth said: "These results are exciting because they show that PARP inhibitors are potentially a powerful targeted treatment with few side effects which may help a broad range of cancer patients. "This shows the real benefits of applying cutting edge science to cancer treatment." And co-researcher Dr Chris Lord added: "This class of drugs could potentially make a big difference for thousands of cancer patients, including some with very limited treatment options. "It shows Breakthrough's focus on turning lab research into patient benefit as quickly as possible is having an impact." Prof Peter Rigby, chief executive of the Institute of Cancer Research, said: "This shows they could benefit far more patients than previously believed." (ANI) Copyright 2009 Asian News International The Asian News International (ANI) agency provides multimedia news to China and 50 bureaus in India. It covers virtually all of South Asia since its foundation and presently claims, on its official website, to be the leading South Asia-wide news agency. (ANI) - All Rights Reserved. Provided by Syndigate.info an Albawaba.com company |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion